{"name":"Ferndale Laboratories, Inc.","slug":"ferndale-laboratories-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"LMX4","genericName":"LMX4","slug":"lmx4","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"LMX4","genericName":"LMX4","slug":"lmx4","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPTmVhZUN5VDdNRlVhbVd1WTNpUTZ0NmIxLVBiampuWFNzNnItUDJoZk8tVTU2WWxYSDNhMDcwUGdPS0hsNk9SQTc3bmw2Nlc2WG96Z05XZWpwSzgwQVRNeDFCWFZicklMWVdWQXJDNEF6MEp2Rjl0Z2RreHFPdmVWd2lBbWc2VmhpME9IZnBPWWRrLXlGRU95M3BEOF9HY2dJTjhZX18zVXQ1aWNGTU9HekdURFRCeGVvc2tsQ1JWOFJxVmkybHhUZ2tEdDNjVy1pX2VjaGpB?oc=5","date":"2024-07-08","type":"pipeline","source":"Healio","summary":"Isotretinoin formulation for acne administered without food may increase patient adherence - Healio","headline":"Isotretinoin formulation for acne administered without food may increase patient adherence","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1TMWcwR2tpTXVfV2RjNDg2ckt6ZkdFWEtjMlJHOHpOdm02WmtmY3BBaVp3b2ZoZHhUQ2Jmc0ZSSXhWYXdmcG95RHktcUN4Z1N4M0cwY00yZWFhbFRqUnRTd2N6NHAwdkZfbGN6MUZtdXJFSTBhUGRoSVlEQko?oc=5","date":"2024-04-22","type":"pipeline","source":"DBusiness Magazine","summary":"Ferndale’s Global Apothecary - DBusiness Magazine","headline":"Ferndale’s Global Apothecary","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNWWwxaGtJeVpPQTB0MjBMODltdkF4cUktb1dfOFFxV0VTRGk5OGJrRVdBZmdmMEZoc29ZZ2VHNVppU29LX2dOZFBEc2tTejVDdW9YWDNLYmVlSkExMEVXYV9lajA4VG5obUdaZF9ES2NuRkJtc3B2cVRJMWRnb1k3RVZ6MXBSYjlWcUw4WWp0cUo5aWpFT2NZYkh5b0FMZXowYUhWSQ?oc=5","date":"2024-04-15","type":"pipeline","source":"BioSpace","summary":"Pharmacogenomics Market Size is Forecasted to Worth USD 35.67 Billion by 2032 - BioSpace","headline":"Pharmacogenomics Market Size is Forecasted to Worth USD 35.67 Billion by 2032","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNbU8xWVdianc1djVkd2dWMTRPempBZ3FCMVU5SDN0T05yS0ZNWHhPbmxiMUtYMVpEZ2F2X2IyZ2Z5Y004Q1VmQmVrTjJzUzZkM1oxTlVwREJHelMyaExPNmk0ZHkzS1lrc2l0eXdkdDZPNDAxNkxPUV9tRHdvQi1nR1Z3dS1yQQ?oc=5","date":"2023-03-17","type":"pipeline","source":"Dermatology Times","summary":"Leon Kircik, MD, FAAD: The Evolving Acne Arsenal - Dermatology Times","headline":"Leon Kircik, MD, FAAD: The Evolving Acne Arsenal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxNTmZ0OUNEZE51eTF4VWdWY29Vc08zems5NDlZU3FLUHhTbmtnakVHSUFjTUhoRzZwaGpsMnhMY3I4VFZwNC1MSnhMRDNIWFV4cWluUkl3Vm5HWko1anJmSWtyb292b2ZzSENnUF9mREp0SHlrRzdYcTBQYjk1QzRlZXhNSldJMWlRSDh0SlptdjJRUU5vVjdrRll3SEc2TlFNSU9DT0c1Nl9lY1ptV3lkWDBqVWhtOTVEWGZrN3ZrZXZVVExLbEFxZnp1cXZWVlVnZXlfT1VTMFNjTF94SGJWY0RCXzcwLW9CV0Y5RUotNHotOUgyc1ZzQVR3RDFiUGk0UkJhOHJWWVFreUF2dEM4bGNteEhRV1hEbnQwTUNfUDduLUcxNXVTVEFhZE1oUQ?oc=5","date":"2020-02-11","type":"trial","source":"PR Newswire","summary":"Crescita Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Studies for its Lead Pipeline Product in Patients with Plaque Psoriasis - PR Newswire","headline":"Crescita Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Studies for its Lead Pipeline Product in P","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}